Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03575832

Watchful Living in Improving Quality of Life in Participants With Localized Prostate Cancer on Active Surveillance and Their Partners

Stage III Prostate Cancer AJCC v8 Clinical Trial

Official title:
Watchful Living: A Lifestyle Intervention for Black and Hispanic Prostate Cancer Patients and Their Partners

Clinical Trial Summary

This pilot trial studies how well Watchful Living works in improving quality of life in participants with prostate cancer that has not spread to other parts of the body who are on active surveillance and their partners. A social support lifestyle intervention (called Watchful Living) may help African American prostate cancer participants and their partners improve their quality of life, physical activity, diet, and inflammation.

Clinical Trial Description

PRIMARY OBJECTIVES: I. To determine the feasibility of recruiting and implementing a lifestyle intervention for prostate cancer patients and their partners. SECONDARY OBJECTIVES: I. To evaluate the preliminary efficacy of a lifestyle intervention in improving diet, physical activity, physical fitness, partner's support, quality of life, and inflammation at the end of the study (month 6). II. To conduct a process evaluation of the lifestyle intervention. III. Explore participants' satisfaction, likes/dislikes, strengths, weaknesses, and areas of improvement regarding the program. OUTLINE: Participants receive an exercise plan and printed materials at baseline. Participants also receive 10 telephone coaching calls over 45-60 minutes weekly during month 1, every 2 weeks during month 2, and every month during months 3-6. Participants complete 2 nutrition counseling sessions before month 3. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03575832
Study type Interventional
Source M.D. Anderson Cancer Center
Contact
Status Active, not recruiting
Phase N/A
Start date January 25, 2018
Completion date December 31, 2025
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03218826 - PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery Phase 1
Recruiting NCT04981834 - Robot-Assisted Radical Prostatectomy With or Without Vesicopexy in Patients With Prostate Cancer N/A
Completed NCT04976257 - Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion Early Phase 1
Recruiting NCT06173362 - Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer Phase 2
Suspended NCT03899987 - Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery Phase 2
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1
Not yet recruiting NCT06129851 - Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer Phase 2
Not yet recruiting NCT05487846 - Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation N/A
Recruiting NCT05946213 - Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer Phase 3
Active, not recruiting NCT03570827 - Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy Phase 2
Recruiting NCT03987386 - Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer Phase 3
Not yet recruiting NCT06325046 - Evaluating Changes in Quality of Life After Near Margin-less Adaptive Radiation Therapy Compared to Standard Stereotactic Ablative Body Radiotherapy in Localized Prostate Cancer N/A
Recruiting NCT04134260 - Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer Phase 3
Completed NCT03177460 - Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer Phase 1
Active, not recruiting NCT05320406 - RElugolix VErsus LeUprolide Cardiac Trial Phase 4
Completed NCT04067960 - Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer Early Phase 1
Suspended NCT04037254 - Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer Phase 2
Recruiting NCT05869682 - Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy Phase 2
Recruiting NCT06389786 - Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer N/A
Recruiting NCT05877144 - Low-Intensity Shockwave Therapy to Treat Erectile Dysfunction and Preserve Erectile Function After Prostate Cancer Surgery N/A